Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvβ3-Targeted Radiotracer 99mTc-3P- RGD2

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 2, 2013, Pages 251-258

  Ji, Shundong ^a   Zhou, Yang ^a   Voorbach, Martin J ^b   Shao, Guoqiang ^a   Zhang, Yumin ^b   Fox, Gerard B ^b   Albert, Daniel H ^b   Luo, Yanping ^b   Liu, Shuang ^a   Mudd, Sarah R ^b  

^a PURDUE UNIVERSITY   (United States)

^b ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINIFANIB; TECHNETIUM 3P ARGINYLGLYCYLASPARTIC ACID 2 TC 99M; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; TREATMENT DURATION; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; DIMERIZATION; FEMALE; GLIOMA; HUMANS; INDAZOLES; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, NUDE; MULTIMODAL IMAGING; OLIGOPEPTIDES; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RADIOPHARMACEUTICALS; TECHNETIUM; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880416633     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.202622     Document Type: Article

References (48)

1. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, and Ghoreishi-Haack NS, et al. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5:995-1006.
2. Battle MR, Goggi JL, Allen L, Barnett J, and Morrison MS (2011) Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled aVb3-integrin and aVb5-integrin imaging agent. J Nucl Med 52: 424-430.
3. Bergers G and Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410.
4. Bergers G, Song S, Meyer-Morse N, Bergsland E, and Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295.
5. Borges E, Jan Y, and Ruoslahti E (2000) Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the b3 integrin through its extracellular domain. J Biol Chem 275:39867-39873.
6. Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H and Langer R (2011) Forty-year journey of angiogenesis translational research. Sci Transl Med 3:114rv3.
7. Chakraborty S, Shi J, Kim YS, Zhou Y, Jia B, Wang F, and Liu S (2010) Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent. Bioconjug Chem 21: 969-978.
8. Clemmons DR, Horvitz G, Engleman W, Nichols T, Moralez A, and Nickols GA (1999) Synthetic aVb3 antagonists inhibit insulin-like growth factor-I-stimulated smooth muscle cell migration and replication. Endocrinology 140:4616-4621.
9. Cybulsky AV, McTavish AJ, and Cyr MD (1994) Extracellular matrix modulates epidermal growth factor receptor activation in rat glomerular epithelial cells. J Clin Invest 94:68-78.
10. Desgrosellier JS and Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22.
11. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, and Distler O (2003) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47:149-161.
12. Dunn IF, Heese O, and Black PM (2000) Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 50:121-137.
13. Ferrara N and Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967-974.
14. Heldin CH, Ostman A, and Rönnstrand L (1998) Signal transduction via plateletderived growth factor receptors. Biochim Biophys Acta 1378:F79-F113.
15. Hernandez-Davies JE, Zape JP, Landaw EM, Tan X, Presnell A, Griffith D, Heinrich MC, Glaser KB, and Sakamoto KM (2011) The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3b-dependent pathway. Mol Cancer Ther 10: 949-959.
16. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, and Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338.
17. Jeswani T and Padhani AR (2005) Imaging tumour angiogenesis. Cancer Imaging 5: 131-138.
18. Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, Li F, Liu S, and Wang F (2011) Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin aVb3-selective radiotracer 99mTc-3PRGD2 in non-human primates. Mol Imaging Biol 13:730-736.
19. Jiang F, Albert DH, Luo Y, Tapang P, Zhang K, Davidsen SK, Fox GB, Lesniewski R, and McKeegan EM (2011) ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models. J Pharmacol Exp Ther 338:134-142.
20. Jones PL, Crack J, and RabinovitchM(1997) Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the aVb3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 139:279-293.
21. Li SG, Ye ZY, Zhao ZS, Tao HQ, Wang YY, and Niu CY (2008) Correlation of integrin beta3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma. World J Gastroenterol 14:421-427.
22. Luo Y, Jiang F, Cole TB, Hradil VP, Reuter D, Chakravartty A, Albert DH, Davidsen SK, Cox BF, and McKeegan EM, et al. (2012) A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model. Cancer Chemother Pharmacol 69:911-921.
23. Ma Q, Ji B, Jia B, Gao S, Ji T, Wang X, Han Z, and Zhao G (2011) Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy. Eur J Nucl Med Mol Imaging 38:2145-2152.
24. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, and Byzova TV (2007) Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 101:570-580.
25. Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, and Wedge SR (2009) Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 50:116-122.
26. O'Connor JP, Jackson A, Parker GJ, and Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189-195.
27. Perrone G, Vincenzi B, Santini D, Verzì A, Tonini G, Vetrani A, and Rabitti C (2004) Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer. Cancer Lett 208:227-234.
28. Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, and Guha A (1997) Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 40:1016-1026.
29. Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, and Osterling DJ, et al. (2007) ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 109:3400-3408.
30. Shao G, Zhou Y,Wang F, and Liu S (2013) Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin aVb3. Mol Imaging 12:39-48.
31. Shattil SJ (1995) Function and regulation of the b3 integrins in hemostasis and vascular biology. Thromb Haemost 74:149-155.
32. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, and Liu S (2009a) 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem 20:1559-1568.
33. Shi J, Wang L, Kim YS, Zhai S, Jia B, Wang F, and Liu S (2009b) 99mTcO(MAG2-3G3- dimer): a new integrin aVb3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. Eur J Nucl Med Mol Imaging 36:1874-1884.
34. Shi J, Zhou Y, Chakraborty S, Kim YS, Jia B, Wang F, and Liu S (2011) Evaluation of 111In-labeled cyclic RGD eptides: effects of peptide and linker multiplicity on their tumor uptake, excretion kinetics and metabolic stability. Theranostics 1:322-340.
35. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, and Bussolino F (1999) Role of aVb3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 18:882-892.
36. Somanath PR, Ciocea A, and Byzova TV (2009) Integrin and growth factor receptor alliance in angiogenesis. Cell Biochem Biophys 53:53-64.
37. Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, Shen B, Niu G, and Chen X (2011) 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 52: 140-146.
38. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, and Coates A, et al. (2011) Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47:2706-2714.
39. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, and Era S (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14:425-431.
40. Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H, Liu Z, Wang F, Chen X, and Liu S (2009) Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm 6:231-245.
41. Weis SM and Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359-1370.
42. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, and Wong J, et al. (2009) Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27:4718-4726.
43. Woodard AS, García-Cardeña G, Leong M, Madri JA, Sessa WC, and Languino LR (1998) The synergistic activity of aVb3 integrin and PDGF receptor increases cell migration. J Cell Sci 111:469-478.
44. Zhou J, Goh BC, Albert DH, and Chen CS (2009) ABT-869, a promising multitargeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol 2:33.
45. Zhou Y, Kim YS, Chakraborty S, Shi J, Gao H, and Liu S (2011) 99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin aVb3 expression. Mol Imaging 10:386-397.
46. Zhou Y, Kim YS, Lu X, and Liu S (2012a) Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties. Bioconjug Chem 23:586-595.
47. Zhou Y, Shao G, and Liu S (2012b) Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin aVb3-Targeted Radiotracer 99mTc-3P-RGD2. Theranostics 2:577-588.
48. Zhu Z, Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, and Liu S, et al. (2012) 99mTc-3P-RGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med 53:716-722.